We have located links that may give you full text access.
The survival rate of patients with beta major thalassemia and thalassemia intermedia and its trend in recent years in Iran.
Epidemiology and Health 2018 October 4
Objectives: Thalassemia is a common genetic disease in Iran, especially in the north and south of the country. The present study seeks to determine the survival rate of patients with thalassemia in high-endemic regions of Iran and its variation in patients born before and after 1971.
Methods: The present historical cohort study examined the health records of patients with major, intermedia and sickle beta thalassemia who had presented to thalassemia centers in the past years and specified their date of death and duration of survival. The data collected were analyzed using the study checklist and the Kaplan-Meier test, the log-rank test and the Chi-square test.
Results: A total of 5491 records were examined in this study, 2647 of which belonged to men and 2634 to women. The mean overall survival was 52.42 years, and the mean survival in cases of major, intermedia and sickle beta thalassemia was 56.59, 53.1 and 50.07 years, respectively. The risk of thalassemia major was 4.22 (P=0.04) and the risk of thalassemia intermedia 0.77 (P=0.7).
Conclusion: Compared to similar studies, the present study shows a higher survival rate in patients with thalassemia. However, comparing the survival of patients born before 1971 and those born after this year does not show any improvements. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including the female gender, a higher level of education, being married and living in metropolises obviate the risk of death at younger ages and improve survival.
Methods: The present historical cohort study examined the health records of patients with major, intermedia and sickle beta thalassemia who had presented to thalassemia centers in the past years and specified their date of death and duration of survival. The data collected were analyzed using the study checklist and the Kaplan-Meier test, the log-rank test and the Chi-square test.
Results: A total of 5491 records were examined in this study, 2647 of which belonged to men and 2634 to women. The mean overall survival was 52.42 years, and the mean survival in cases of major, intermedia and sickle beta thalassemia was 56.59, 53.1 and 50.07 years, respectively. The risk of thalassemia major was 4.22 (P=0.04) and the risk of thalassemia intermedia 0.77 (P=0.7).
Conclusion: Compared to similar studies, the present study shows a higher survival rate in patients with thalassemia. However, comparing the survival of patients born before 1971 and those born after this year does not show any improvements. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including the female gender, a higher level of education, being married and living in metropolises obviate the risk of death at younger ages and improve survival.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app